Abstract
Spinal muscular atrophy (SMA) is an inherited motor neuron disease caused by mutation of the telomeric copy of the survival motor neuron gene (SMN1). Although a centromeric copy of the survival motor neuron gene (SMN2) is retained in all patients with SMA, it differs from SMN1 at a critical nucleotide such that the majority of SMN2 transcripts lack exon 7 and encode an unstable, truncated protein. Here, we show that valproic acid increases levels of exon 7-containing SMN transcript and SMN protein in type I SMA patient-derived fibroblast cell lines. Valproic acid may increase SMN levels both by activating the SMN promoter and by preventing exon 7 skipping in SMN transcripts. Valproic acid and related compounds warrant further investigation as potential treatment for SMA.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Anticonvulsants / pharmacology*
-
Cell Line
-
Child, Preschool
-
Cyclic AMP Response Element-Binding Protein
-
Dose-Response Relationship, Drug
-
Fibroblasts / drug effects*
-
Fibroblasts / physiology
-
Humans
-
Immunoblotting
-
Immunohistochemistry
-
Infant
-
Infant, Newborn
-
Nerve Tissue Proteins / biosynthesis
-
Nerve Tissue Proteins / drug effects*
-
Promoter Regions, Genetic
-
RNA-Binding Proteins
-
Reverse Transcriptase Polymerase Chain Reaction
-
SMN Complex Proteins
-
Spinal Muscular Atrophies of Childhood / genetics*
-
Survival of Motor Neuron 1 Protein
-
Survival of Motor Neuron 2 Protein
-
Time Factors
-
Transcription, Genetic / drug effects
-
Transcription, Genetic / genetics
-
Valproic Acid / pharmacology*
Substances
-
Anticonvulsants
-
Cyclic AMP Response Element-Binding Protein
-
Nerve Tissue Proteins
-
RNA-Binding Proteins
-
SMN Complex Proteins
-
SMN1 protein, human
-
SMN2 protein, human
-
Survival of Motor Neuron 1 Protein
-
Survival of Motor Neuron 2 Protein
-
Valproic Acid